Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia

  — Safe and Tolerable: MyopiaX-1 proof-of-concept clinical trial (NCT04967287) supports MyopiaX’s excellent safety and tolerability profile with no untoward safety events. — Novel Approach: Dopavision’s approach to delivering targeted photobiomodulation to the eye shows signals of clinical effect on the rate of myopia progression. — New Alternative: The intervention delivered in an easy to […]